Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Neostigmine in Peribulbar Block for Vitreoretinal Surgery
NCT06501352Phase 1Completed
- Sponsor
- Ain Shams University
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of dexmedetomidine and neostigmine in vitreoretinal disease (VRD) (3 arms), sponsored by Ain Shams University. Primary endpoints: Onset of sensory block at 12 hours, Duration of sensory block at 12 hours and 2 more. Started Jan 2023; status: completed.
02
Drugs
dexmedetomidineneostigmine
03
Conditions
vitreoretinal disease (VRD)
Beyond the preview
Go deeper on NCT06501352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06501352.